CD274 and neoplasm: In our case, despite the absence of predictive biomarkers for immunotherapy efficacy, such as PD-L1 positivity or mismatch repair (MMR) deficiency, the tumor’s aggressiveness and limited systemic options justified exploring immunotherapy.